12/18
03:28 pm
thtx
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment [Canadian Business Journal (Canada)]
Low
Report
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment [Canadian Business Journal (Canada)]
12/18
01:30 pm
thtx
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Neutral
Report
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
12/10
05:28 pm
thtx
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA [Canadian Business Journal (Canada)]
Neutral
Report
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA [Canadian Business Journal (Canada)]
12/10
03:15 pm
thtx
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
Medium
Report
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
12/9
07:42 am
thtx
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer [Yahoo! Finance]
Medium
Report
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer [Yahoo! Finance]
12/9
07:30 am
thtx
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
Medium
Report
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
12/4
09:28 am
thtx
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada [Canadian Business Journal (Canada)]
Low
Report
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada [Canadian Business Journal (Canada)]
12/4
07:30 am
thtx
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
Neutral
Report
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
12/3
04:38 pm
thtx
Theratechnologies Announces Resumed Production of EGRIFTA SV® [Yahoo! Finance]
Medium
Report
Theratechnologies Announces Resumed Production of EGRIFTA SV® [Yahoo! Finance]
12/3
04:30 pm
thtx
Theratechnologies Announces Resumed Production of EGRIFTA SV®
Medium
Report
Theratechnologies Announces Resumed Production of EGRIFTA SV®
12/2
09:28 am
thtx
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec [Canadian Business Journal (Canada)]
Medium
Report
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec [Canadian Business Journal (Canada)]
12/2
07:30 am
thtx
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
Medium
Report
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
11/26
07:43 am
thtx
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review [Yahoo! Finance]
Medium
Report
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review [Yahoo! Finance]
11/26
07:30 am
thtx
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
Medium
Report
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
11/25
05:54 am
thtx
Theratechnologies Inc. (TSE:TH) Has Found A Path To Profitability [Yahoo! Finance]
Neutral
Report
Theratechnologies Inc. (TSE:TH) Has Found A Path To Profitability [Yahoo! Finance]
10/17
02:05 pm
thtx
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV [Financial Post (Toronto, Ontario, Canada)]
10/17
02:00 pm
thtx
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
Low
Report
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
10/17
07:35 am
thtx
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance [Financial Post (Toronto, Ontario, Canada)]
10/17
07:30 am
thtx
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
Low
Report
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
10/10
10:49 am
thtx
Theratechnologies Inc. (THTX) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Theratechnologies Inc. (THTX) Q3 2024 Earnings Call Transcript [Seeking Alpha]
10/9
07:36 am
thtx
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV [Financial Post (Toronto, Ontario, Canada)]
10/9
07:30 am
thtx
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
Medium
Report
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV